|
original article |
Date |
Title |
Authors Max. 6 Authors |
1 |
[GO] |
2023―Apr―19 |
Factors associated with adverse outcome among hospitalized patients with moderate to severe COVID-19 |
S. A. Mishinova, Yu. M. Gomon, A. S. Kolbin, E. V. Verbitskaya, T. I. Galimov |
2 |
[GO] |
2023―Mar―02 |
Specifics of motivation of volunteers participating in in a clinical trial of the COVID-19 vaccine |
Y. D. Belousova, V. V. Rafalsky, E. D. Kislova |
3 |
[GO] |
2022―Nov―15 |
The use of a new oral antiviral drug molnupiravir in the treatment of COVID-19 from a safety perspective |
A. L. Khokhlov, J. V. Rybachkova |
4 |
[GO] |
2022―May―02 |
Lifestyle Changes in Medical Students during the COVID-19 Pandemic |
V. A. Sergeeva, T. E. Lipatova |
5 |
[GO] |
2022―Feb―14 |
Analysis of the effectiveness of vaccination against COVID-19 based on real-world data in St. Petersburg |
A. A. Kurylev, A. A. Zhuravkov, A. S. Kolbin |
6 |
[GO] |
2021―Aug―13 |
COVID-19: economic aspects of influenza vaccine prevention |
E. A. Zhidkova, E. M. Gutor, Yu. A. Tkachenko, I. V. Rogova, I. A. Popova, K. G. Gurevich |
7 |
[GO] |
2021―Mar―12 |
Socioeconomic and global burden of COVID-19 |
A. S. Kolbin, Yu. M. Gomon, Yu. E. Balykina, D. Yu. Belousov, V. V. Strizheletskiy, I. G. Ivanov |
8 |
[GO] |
2020―Oct―28 |
Possibility to use direct oral anticoagulants to prevent thromboembolic events in patients with COVID-19 |
V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev |
9 |
[GO] |
2020―Oct―28 |
Current and future use of angiotensin II receptor blockers in patients with COVID-19 |
A. V. Matveev, V. A. Otdelenov, D. A. Sychev |
10 |
[GO] |
2020―Oct―28 |
Possibilities for the use of tofacitinib in patients with COVID-19 |
A. V. Matveev, Yu. Yu. Kiselev, D. A. Sychev |
11 |
[GO] |
2020―Oct―28 |
Adjusting the role of hydroxychloroquine with or without azithromycin in patients with COVID-19 |
V. A. Otdelenov, Yu. Yu. Kiselev, K. B. Mirzaev, A. V. Matveev, D. A. Sychev |
12 |
[GO] |
2020―Oct―28 |
Possibilities for the use of anakinra in COVID-19 |
V. A. Otdelenov, A. V. Matveev, D. A. Sychev |
13 |
[GO] |
2020―Oct―28 |
Rationality of routine clinical use of olokizumab in COVID-19 |
V. M. Tsvetov, A. V. Matveev, D. A. Sychev |
14 |
[GO] |
2020―Oct―28 |
Current and future use of colchicine in patients with COVID-19 |
Yu. Yu. Kiselev, A. V. Matveev, D. A. Sychev |
15 |
[GO] |
2020―Oct―28 |
Current and future use of umifenovir in patients with COVID-19 |
Yu. Yu. Kiselev, K. A. Zagorodnikova, D. V. Ivashchenko, A. V. Krykov, I. N. Sychev, A. S. Matveev, K. B. Mirzaev, V. A. Otdelenov, V. M. Tsvetov, A. V. Dmitriev, V. V. Poroikov, D. A. Sychev |
16 |
[GO] |
2020―Oct―28 |
Current and future use of vitamin D3 in patients with COVID-19 |
I. N. Sychev, A. V. Matveev, D. A. Sychev |
17 |
[GO] |
2020―Oct―28 |
Current and future use of dipyridamole in patients with COVID-19 |
I. S. Burashnikova, V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev |
18 |
[GO] |
2020―Oct―28 |
Dexamethasone use in patients with COVID-19 |
V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev |
19 |
[GO] |
2020―Oct―28 |
Current and future use of remdesivir in patients with COVID-19 |
V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev |
20 |
[GO] |
2020―Oct―28 |
Current and future use of favipiravir in patients with COVID-19 |
A. V. Matveev, Yu. Yu. Kiselev, D. A. Sychev |
21 |
[GO] |
2020―Oct―28 |
Use of unlicensed drugs and off-label drug use: focus on COVID-19 |
S. A. Mishinova, A. A. Zhuravkov, V. K. Zhuravko |
22 |
[GO] |
2020―Oct―28 |
Anticoagulant deprescribing algorithm in patients with COVID-19 after hospital discharge |
A. V. Krykov, V. A. Otdelenov, D. A. Sychev |
23 |
[GO] |
2020―Oct―28 |
Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis |
V. M. Tsvetov, I. N. Sychev, D. A. Sychev |
24 |
[GO] |
2020―Oct―28 |
Current and future use of aminodihydrophthalazindione sodium in patients with COVID-19, including for «cytokine storm» therapy |
V. M. Tsvetov, Yu. Yu. Kiselev, K. B. Mirzaev, D. A. Sychev |
25 |
[GO] |
2020―Oct―28 |
Possibility to use barycytinib in patients with COVID-19, including for treatment of «cytokine storm» |
V. A. Otdelenov, V. M. Tsvetov, D. A. Sychev |
26 |
[GO] |
2020―Oct―28 |
Rationale for use mefloquine for COVID-19 treatment |
V. A. Otdelenov, K. B. Mirzaev, A. V. Dmitriev, V. V. Poroikov, D. A. Sychev |
27 |
[GO] |
2020―Oct―28 |
Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention |
K. B. Mirzaev, D. A. Sychev |
28 |
[GO] |
2020―Oct―28 |
Methylprednisolone in acute respiratory distress-syndrome in COVID-19: rationales for use, optimal dosage regimens, combined use with tocilizumab |
K. B. Mirzaev, Yu. Yu. Kiselev, D. A. Sychev |
29 |
[GO] |
2020―Oct―28 |
Is it possible to use riamilovir to prevent infection and treat COVID-19? |
V. M. Tsvetov, K. B. Mirzaev, D. A. Sychev |
30 |
[GO] |
2020―Oct―28 |
Can inhalations of hyaluronidase be used in acute respiratory distress-syndrome in patients with COVID-19? |
Yu. Yu. Kiselev, K. B. Mirzaev, D. A. Sychev |
31 |
[GO] |
2020―Oct―28 |
Could canakinumab be used for COVID-19? |
V. A. Otdelenov, K. B. Mirzaev, D. A. Sychev |
32 |
[GO] |
2020―Oct―28 |
Possibility for the use of bromhexine to prevent infection with SARS-CoV-2 |
K. A. Zagorodnikova, K. B. Mirzaev, D. A. Sychev |
33 |
[GO] |
2020―Oct―28 |
Possibilities for the use of hydroxychloroquine for pre- and postexposure prophylaxis of SARS-CoV-2 infection among exposed contacts and healthcare personnel |
V. A. Otdelenov, A. V. Krykov, D. A. Sychev |
34 |
[GO] |
2020―May―30 |
Socio-economic burden of COVID-19 in the Russian Federation |
A. S. Kolbin, D. Yu. Belousov, Yu. M. Gomon, Yu. E. Balykina, I. G. Ivanov |